Disease severity in moderate-to-severe plaque psoriasis: results from the Belgian REDISCOVER study

被引：0

作者：

Hillary, Tom ^{[1
]}

Ghys, Liesbeth ^{[2
]}

Willaert, Fabienne ^{[3
]}

Swimberghe, Sandra

Lecuyer, Myriam

Ghislain, Pierre-Dominique ^{[4
]}

Morrens, Joachim ^{[2
]}

Lambert, Jo ^{[5
]}

机构：

[1] Univ Hosp Leuven, Leuven, Belgium

[2] Abbvie Belgium, Brussels, Belgium

[3] Univ Libre Bruxelles, Erasme Hosp, Dermatol, Brussels, Belgium

[4] Catholic Univ Louvain, Dermatol, Clin St Luc, Brussels, Belgium

[5] Ghent Univ Hosp, Dermatol, Ghent, Belgium

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

40351

引用

页码：AB37 / AB37

页数：1

共 50 条

[21] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
Dauden, E.
Prieto-Perez, R.
Llamas-Velasco, M.
Cabaleiro, T.
Abad-Santos, F.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
[22] Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
Gisondi, Paolo
Girolomoni, Giampiero
DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1763 - 1770
[23] Therapeutic inertia in the management of moderate-to-severe plaque psoriasis
Halioua, B.
Corgibet, F.
Maghia, R.
Hello, S.
Caillet, G.
Nicolas, C.
Riboulet, J. -L.
Mahe, E.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (01) : E30 - E32
[24] Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
Chiricozzi, Andrea
Balato, Anna
Conrad, Curdin
Conti, Andrea
Dapavo, Paolo
Ferreira, Paulo
Gaiani, Francesca Maria
Leite, Luiz
Malagoli, Piergiorgio
Mendes-Bastos, Pedro
Megna, Matteo
Messina, Francesco
Nidegger, Alessia
Odorici, Giulia
Panduri, Salvatore
Piaserico, Stefano
Piscitelli, Leonardo
Prignano, Francesca
Ribero, Simone
Valerio, Joana
Torres, Tiago
JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (05) : 476 - 483
[25] Bimekizumab in patients with moderate-to-severe plaque psoriasis by bodyweight: pooled results from phase III trials
Pinter, A.
Strober, B.
Rosmarin, D.
Gisondi, P.
Vanvoorden, V.
Peterson, L.
Madden, C.
de Cuyper, D.
Warren, R.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E48 - E49
[26] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
Blauvelt, Andrew
Papp, Kim A.
Gooderham, Melinda
Langley, Richard G.
Leonardi, Craig
Lacour, Jean-Philippe
Philipp, Sandra
Tyring, Stephen
Bukhalo, Michael
Wu, Jashin J.
Bagel, Jerry
Frankel, Ellen H.
Pariser, David
Flack, Mary
Scherer, Joseph
Geng, Ziqian
Gu, Yihua
Camez, Anne
Thompson, Elizabeth H. Z.
ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
[27] Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
Blauvelt, Andrew
Reich, Kristian
Papp, Kim A.
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Gooderham, Melinda
Li, Qing
Cichanowitz, Nicole
la Rosa, Carmen
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB226 - AB226
[28] WORK PRODUCTIVITY IN BRAZILIAN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Lopes, N.
Antonio, J. R.
Fabricio, L.
Azulay-Abulafia, L.
Dias, L. L.
Pertel, P.
VALUE IN HEALTH, 2017, 20 (09) : A902 - A902
[29] Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
Heydendael, VMR
Spuls, PI
Opmeer, BC
de Borgie, CAJM
Reitsma, JB
Goldschmidt, WFM
Bossuyt, PMM
Bos, JD
de Rie, MA
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 658 - 665
[30] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
Kory P. Schrom
Avi Bitterman
Neil J. Korman
Current Dermatology Reports, 2019, 8 : 6 - 13

← 1 2 3 4 5 →